Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity

Encephalopathy of prematurity (EoP) affects approximately 30% of infants born

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuroinflammation 2022-10, Vol.19 (1), p.265-16, Article 265
Hauptverfasser:	Yates, Abi G, Kislitsyna, Elena, Alfonso Martin, Carla, Zhang, Jiaying, Sewell, Amy L, Goikolea-Vives, Ane, Cai, Valerie, Alkhader, Lama F, Skaland, Aleksander, Hammond, Basil, Dimitrova, Ralica, Batalle, Dafnis, Fernandes, Cathy, Edwards, A David, Gressens, Pierre, Thornton, Claire, Stolp, Helen B
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetates - pharmacology Acetates - therapeutic use Alzheimer's disease Animal cognition Animals Asthma Body weight Brain Diseases Complications and side effects Cytokines Diagnosis Diffusion MRI Disease Models, Animal Encephalopathy Experiments Female Fetuses Gray Matter Health aspects Humans IL-1β Infant, Newborn Infants (Premature) Inflammation Inflammation - drug therapy Interleukin 6 Male Mice Montelukast Neurogenesis Neuropathology Parvalbumin Patient outcomes Plasma Premature birth Premature Birth - drug therapy Preterm brain injury Proteins Quinolines - pharmacology Quinolines - therapeutic use Spatial discrimination learning Substantia grisea Traumatic brain injury Tumor necrosis factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Encephalopathy of prematurity (EoP) affects approximately 30% of infants born
ISSN:	1742-2094 1742-2094
DOI:	10.1186/s12974-022-02625-5